United Orthopedic (UOC) launched “Prospective Post Approval Clinical Follow-Up Study of the Commercially Available U2 Knee™ System – ‘U Propel Study’,” and enrolled its first patient. The prospective, single arm, multi-center, postmarket study will evaluate short- and long-term clinical performance and implant survivorship of the U2 Knee in primary total knee arthroplasty.
U-Propel will enroll up to 200 patients with follow-up out to five years. Outcomes will be analyzed and published in three phases: after six-week follow-up; two-year follow-up and at conclusion of the study. On clinicaltrials.gov, the study’s identifier is NCT03060057.
UOC is also conducting a U.S. follow-up study of its U-Motion II+ Acetabular System and UTF Reduced Stem in primary total hip arthroplasty patients. Estimated primary completion for that study is January 2019.
Source: United Orthopedic Corporation
United Orthopedic (UOC) launched "Prospective Post Approval Clinical Follow-Up Study of the Commercially Available U2 Knee™ System – 'U Propel Study'," and enrolled its first patient. The prospective, single arm, multi-center, postmarket study will evaluate short- and long-term clinical performance and implant survivorship of the U2 Knee...
United Orthopedic (UOC) launched “Prospective Post Approval Clinical Follow-Up Study of the Commercially Available U2 Knee™ System – ‘U Propel Study’,” and enrolled its first patient. The prospective, single arm, multi-center, postmarket study will evaluate short- and long-term clinical performance and implant survivorship of the U2 Knee in primary total knee arthroplasty.
U-Propel will enroll up to 200 patients with follow-up out to five years. Outcomes will be analyzed and published in three phases: after six-week follow-up; two-year follow-up and at conclusion of the study. On clinicaltrials.gov, the study’s identifier is NCT03060057.
UOC is also conducting a U.S. follow-up study of its U-Motion II+ Acetabular System and UTF Reduced Stem in primary total hip arthroplasty patients. Estimated primary completion for that study is January 2019.
Source: United Orthopedic Corporation
You are out of free articles for this month
Subscribe as a Guest for $0 and unlock a total of 5 articles per month.
You are out of five articles for this month
Subscribe as an Executive Member for access to unlimited articles, THE ORTHOPAEDIC INDUSTRY ANNUAL REPORT and more.
JV
Julie Vetalice is ORTHOWORLD's Editorial Assistant. She has covered the orthopedic industry for over 20 years, having joined the company in 1999.